Advertisement

Gynecological Cancer

  • Julio C. de la Torre-MonteroEmail author
Chapter
Part of the Principles of Specialty Nursing book series (PSN)

Abstract

Gynecological cancer is one of the greatest challenges in treatment, as well as in prevention and early diagnosis, of the set of all diagnosed cancers. At the beginning of the twenty-first century, we have witnessed the arrival of new treatments, new surgical techniques, more precise tools for diagnosis and prognosis, and the great development of antitumoral products, which give patients new perspectives on their prognosis and evolution, including improvement in the patient’s quality of life. All of these are important factors in their recovery.

It is important that we know what resources are available: accurate diagnostic tools such as positron emission tomography–computed tomography (PET-CT), effective vaccination programs against the viruses that trigger various types of tumors, and also treatments based on surgery, chemotherapy, monoclonal antibodies, and other tools that enable us to offer patients confidence based on the safety and efficacy of the combination of these treatments.

Cancer prevention—through vaccination campaigns and, above all we can do, education as a key point—is the way to achieve a healthy population, as well as a better quality of life for patients.

Keywords

Gynecological tumors Cancer treatment Sexual education HPV vaccines Cancer prevention Oncology nursing 

References

  1. 1.
    Jaffe S. Planning for US precision medicine initiative underway. Lancet. 2015;385(9986):2448–9.CrossRefGoogle Scholar
  2. 2.
    Taking personalized medicine to heart. Nat Med. 2018;24:113.Google Scholar
  3. 3.
    Genetics Home Reference. What is the difference between precision medicine and personalized medicine? What about pharmacogenomics? https://ghr.nlm.nih.gov/primer/precisionmedicine/precisionvspersonalized. Accessed 26 Jan 2019.
  4. 4.
    Bender E. Cancer immunotherapy. Nature. 2017;552(7685):S61.CrossRefGoogle Scholar
  5. 5.
    McEvoy MD, Cannon L, Mac Dermott ML. The professional role for nurses in clinical trials. Semin Oncol Nurs. 1991;7(4):268–74.CrossRefGoogle Scholar
  6. 6.
    National Comprehensive Cancer Network [NCCN]. NCCN clinical practice guidelines in oncology (NCCN guidelines®). Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Version 2.2018—March 9, 2018. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed 26 Jan 2019.
  7. 7.
    van der Burg MEL, de Wit R, van Putten WL, Logmans A, Kruit WH, Stoter G, Verweij J. Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer. Br J Cancer. 2002;86(1):19–25.  https://doi.org/10.1038/sj.bjc.6600002.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Park YC, Parekh TV, Poveda AM. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer. 2012;48(15):2361–8.  https://doi.org/10.1016/j.ejca.2012.04.001.CrossRefPubMedGoogle Scholar
  9. 9.
    National Comprehensive Cancer Network [NCCN]. NCCN clinical practice guidelines in oncology (NCCN guidelines®). Vulvar cancer (squamous cell carcinoma). Version 2.2019—December 17, 2018. https://www.nccn.org/professionals/physician_gls/pdf/vulvar.pdf. Accessed 26 Jan 2019.
  10. 10.
    US Food and Drug Administration [FDA]. FDA approves rucaparib for maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm603997.htm. Accessed 26 Jan 2019.
  11. 11.
    Smith ER, George SH, Kobetz E, Xu XX. New biological research and understanding of Papanicolaou’s test. Diagn Cytopathol. 2018;46(6):507–15.  https://doi.org/10.1002/dc.23941.CrossRefPubMedGoogle Scholar
  12. 12.
    Chen M, Lee K, Lu C, Wang T, Huang S, Chen C. The bidirectional association among female hormone–related cancers: breast, ovary, and uterine corpus. Cancer Med. 2018;7(6):2299–306.  https://doi.org/10.1002/cam4.1473.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Berger AC, Caesar-Johnson SJ, et al. A comprehensive pan-cancer molecular study of gynecologic and breast cancers. Cancer Cell. 2018;33(4):690–705.E9.CrossRefGoogle Scholar
  14. 14.
    US Food and Drug Administration [FDA]. Human papillomavirus vaccine. https://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm172678.htm. Accessed 26 Jan 2019.
  15. 15.
    Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescent’s vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309(17):1793–802.CrossRefGoogle Scholar
  16. 16.
    Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30(Suppl 5):F123–38.CrossRefGoogle Scholar
  17. 17.
    Newman PA, Logie CH, Lacombe-Duncan A, Baiden P, Tepjan S, Rubincam C, Doukas N, Asey F. Parents’ uptake of human papillomavirus vaccines for their children: a systematic review and meta-analysis of observational studies. BMJ Open. 2018;8(4):e019206.  https://doi.org/10.1136/bmjopen-2017-019206.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Rahn DD, Carberry C, Sanses TV, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol. 2014;124(6):1147–56.  https://doi.org/10.1097/AOG.0000000000000526.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Johansen N, Liavaag AH, Mørkrid L, Michelsen TM. Hormone levels and sexual functioning after risk-reducing salpingo-oophorectomy. Sex Med. 2018;6(2):143–53.  https://doi.org/10.1016/j.esxm.2018.02.002.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Ulrich CM, et al. Nurse practitioners’ attitudes about cancer clinical trials and willingness to recommend research participation. Contemp Clin Trials. 2012;33(1):76–84.CrossRefGoogle Scholar
  21. 21.
    Diver EJ, Hinchcliff EM, Gockley AA, Melamed A, Contrino L, Feldman S, et al. Assessment of treatment factors and clinical outcomes in cervical cancer in older women compared to women under 65 years old. J Geriatr Oncol. 2018;9(5):516–9.CrossRefGoogle Scholar
  22. 22.
    Pimple S, Mishra G, Shastri S. Global strategies for cervical cancer prevention. Curr Opin Obstet Gynecol. 2016;28(1):4–10.CrossRefGoogle Scholar
  23. 23.
    Tahmasebi M, Yarandi F, Eftekhar Z, Montazeri A, Namazi H. Quality of life in gynecologic cancer patients. Asian Pac J Cancer Prev. 2007;8(4):591–2.PubMedGoogle Scholar
  24. 24.
    Tabano M, Condosta D, Coons M. Symptoms affecting quality of life in women with gynecologic cancer. Semin Oncol Nurs. 2002;18(3):223–30.CrossRefGoogle Scholar
  25. 25.
    Rahman Z, Singh U, Qureshi S, Nisha, Srivastav K, Nishchal A. Assessment of quality of life in treated patients of cancer cervix. J Mid-Life Health. 2017;8(4):183–8.  https://doi.org/10.4103/jmh.JMH_40_17.CrossRefGoogle Scholar
  26. 26.
    European Organisation for Research and Treatment of Cancer [EORTC] Quality of Life Group. Questionnaires. https://qol.eortc.org/questionnaires/. Accessed 26 Jan 2019.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.San Juan de Dios School of Nursing and Physical TherapyComillas Pontifical UniversityMadridSpain

Personalised recommendations